Biotinylated radioconjugates

Biotinylated radioconjugates are a class of diagnostic and therapeutic agents used in multi-step pre-targeting strategies to improve the precision of radioimmunotherapy and molecular imaging (Boerman et al., 2003, J Nucl Med). These molecules consist of a biotin moiety linked to a chelator that carries a radionuclide, such as Lutetium-177 or Yttrium-90 (Goldenberg et al., 2006, J Clin Oncol). They are not biological targets themselves but are designed to bind with extreme affinity to avidin or streptavidin that has been pre-localized to a tumor site via a primary targeting agent (Green, 1975, Adv Protein Chem). This approach decouples the slow pharmacokinetics of large targeting molecules like antibodies from the fast-clearing radioactive probe, thereby maximizing the radiation dose to the tumor while minimizing systemic exposure (Paganelli et al., 1999, Cancer Biother Radiopharm). Clinical applications primarily focus on oncology, where they help overcome the limitations of direct radioimmunotherapy, such as myelotoxicity. However, challenges remain regarding the immunogenicity of the bacterial-derived streptavidin and the potential for interference from endogenous biotin in the blood (Lazzeri et al., 2004, Eur J Nucl Med Mol Imaging).

Other names

Radiolabeled biotinBiotin-radionuclide conjugatesBiotinylated radiopharmaceuticalsBiotin-chelator-radionuclide complexes

Biotinylated radioconjugates function through the high-affinity avidin-biotin interaction (Kd ~10^-15 M) in a pre-targeting system (Green, 1975, Adv Protein Chem). A primary targeting agent, such as a streptavidin-conjugated monoclonal antibody, is first administered to localize at the target tissue (e.g., a tumor). After the primary agent has cleared from the circulation, the biotinylated radioconjugate is administered; it binds rapidly and specifically to the localized streptavidin to deliver a concentrated dose of ionizing radiation for imaging or therapy (Boerman et al., 2003, J Nucl Med). The excess radioconjugate is rapidly cleared through the kidneys, which significantly reduces the radiation dose to non-target tissues compared to direct radioimmunotherapy (Goldenberg et al., 2006, J Clin Oncol).